BioPharmaStock
HomeAsk About StockNewsIdeasHistoryFDA DesignationsElite Program

ICU

No price yet

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

  • SeaStar Medical supported advances in critical care for pediatric patients with acute kidney injuryJul 14, 2026
  • SeaStar Medical fulfilled the FDA enrollment requirement for the SAVE surveillance registry assessing QUELIMMUNE safety in pediatric AKIMar 5, 2026
  • SeaStar Medical announced FDA approval of reduction in mandatory enrollment for SAVE Surveillance Registry evaluating QUELIMMUNE™ safety for pediatric AKIDec 2, 2025
  • SeaStar Medical reports DSMB recommendation to continue NEUTRALIZE-AKI pivotal trial in adult acute kidney injurySep 25, 2025
  • SeaStar Medical to present early SAVE registry data of QUELIMMUNE in pediatric acute kidney injury at 5th International Symposium on Acute Kidney Injury in ChildrenSep 23, 2025

    Bio Pharma Stock

    Where Science Meets Investing.

    BioPharmaStock is a specialized biopharmaceutical investment intelligence company focused exclusively on publicly traded biotechnology and pharmaceutical companies. Our research team continuously analyzes clinical trials, FDA regulatory events, scientific publications, corporate developments, and market catalysts to deliver timely research and exclusive insights for investors seeking opportunities in one of the world's most knowledge-intensive sectors.

    ALNJAM ALAALI SOFTWARE DESIGN CO. L.L.C, UAE, Abu Dhabi

    BioPharmaStock LogoBioPharmaStock Logo

    Quick Links

    • Home
    • Ask About Stock
    • News
    • Ideas
    • History
    • FDA Designations
    • Elite Program

    Contact Us

    Email: info@biopharmastock.com

    Phone: +971 50 936 3328

    Join Our Community→

    Follow Us

    Get the App

    Instant notifications on your phone

    Download on theApp StoreGet it onGoogle Play

    © 2026 Bio Pharma Stock. All rights reserved. Policy